OcuTherm®

Ophthalmologist-Designed
Clinically and Laboratory Tested

OcuTherm®

Ophthalmologist-Designed
Clinically and Laboratory Tested

OcuTherm®

Ophthalmologist-Designed

Clinically and Laboratory Tested

Our Mission

References at Bottom of Page

Our Mission

References at Bottom of Page

Our Mission

References at Bottom of Page

Daily signals of ocular discomfort, including simple eye strain, can lead to “vicious cycles” that overwhelm the nervous system. Over time, this process can even contribute to depression. (Refs. A 1-6)

However, positive sensory input may help the body override negative pain signals from the eye region, and restore balance to the system. (Refs. A 7-10)

To fight back against ocular discomfort, we listened to the needs of hundreds of patients, and spent years working on these elements of ocular thermal therapy (Refs. A 11-13):

  • Thermal Consistency of OcuTherm Gel, whether heated, cool, or cold

  • Precise Eyelid Conformation upon virtually any size or shape of face

  • Evenly-Distributed “Presence” of Gel across both eyes

  • Sensory Touch (“Skin-Feel”) of all materials, especially those that directly contact the eyelids and face during use

Daily symptoms of ocular discomfort, including simple eye strain, can lead to “vicious cycles” that overwhelm the nervous system. Over time, this process can even contribute to depression. (Refs. A 1-6)

However, positive sensory input may help the body override negative pain signals from the eye region, and restore balance to the system. (Refs. A 7-10)

To fight back against ocular discomfort, we listened to the needs of hundreds of patients, and spent years working on these elements of ocular thermal therapy (Refs. A 11-13):

  • Thermal Consistency of OcuTherm Gel, whether heated, cool, or cold

  • Precise Eyelid Conformation upon virtually any size or shape of face

  • Evenly-Distributed “Presence” of Gel across both eyes

  • Sensory Touch (“Skin-Feel”) of all materials, especially those that directly contact the eyelids and face during use

Daily signals of ocular discomfort, including simple eye strain, can lead to “vicious cycles” that overwhelm the nervous system. Over time, this process can even contribute to depression.
(Refs. A 1-6)

However, positive sensory input may help the body override negative pain signals from the eye region, and restore balance to the system. (Refs. A 7-10)

To fight back against ocular discomfort, we listened to the needs of hundreds of patients, and spent years working on these elements of ocular thermal therapy (Refs. A 11-13):

  • Thermal Consistency of OcuTherm Gel, whether heated, cool, or cold

  • Precise Eyelid Conformation upon virtually any size or shape of face

  • Evenly-Distributed “Presence” of Gel across both eyes

  • Sensory Touch (“Skin-Feel”) of all materials, especially those that directly contact the eyelids and face during use

OcuTherm’s
Suspended-Gel™ Technology

Here are 3 principal features of our technology:

1. Full Sensory Effectiveness. The ocular surface is the most sensitive area of your body, with 10 times the sensory nerve density of your fingertips. To your nervous system, ocular thermal therapy may be considered the rough equivalent of a full-body thermal treatment. This makes it a highly efficient way to re-set your entire system. Treatments can be as quick as one minute, or much longer if desired.

2. Unbeatable Thermal Conductivity. Choose your temperature for each treatment. At room temperature, the mask produces treatments that are cool and settling. With a quick microwave heating, the mask will deliver a steam-bath effect that suffuses your entire eye region. Refrigerating the mask for 5 minutes or more is your entry into cold therapy to a level you prefer. If refrigerated overnight, the mask produces a bracingly cold and rejuvenating “ice-plunge” experience. Heated, Cool, or Cold, OcuTherm users say you can feel your entire body relax into each treatment.

3. Anatomic Perfection. The OcuTherm mask maintains sensory contact throughout your entire eye region, but without excessive pressure on the eyes themselves. What you get is a perfectly balanced experience that respects your ocular anatomy.

We spent years of careful research to provide you with prompt, accurate, and intensive relief, so you can get back to your life quickly and with renewed energy.

OcuTherm’s
Suspended-Gel™ Technology

OcuTherm’s
Suspended-Gel™ Technology

Here are 3 principal features of our technology:

1. Full Sensory Effectiveness. The ocular surface is the most sensitive area of your body, with 10 times the sensory nerve density of your fingertips. To your nervous system, ocular thermal therapy may be considered the rough equivalent of a full-body thermal treatment. This makes it a highly efficient way to re-set your entire system. Treatments can be as quick as one minute, or much longer if desired.

2. Unbeatable Thermal Conductivity. Choose your temperature for each treatment. At room temperature, the mask produces treatments that are cool and settling. With a quick microwave heating, the mask will deliver a steam-bath effect that suffuses your entire eye region. Refrigerating the mask for 5 minutes or more is your entry into cold therapy to a level you prefer. If refrigerated overnight, the mask produces a bracingly cold and rejuvenating “ice-plunge” experience. Heated, Cool, or Cold, OcuTherm users say you can feel your entire body relax into each treatment.

3. Anatomic Perfection. The OcuTherm mask maintains sensory contact throughout your entire eye region, but without excessive pressure on the eyes themselves. What you get is a perfectly balanced experience that respects your ocular anatomy.

We spent years of careful research to provide you with prompt, accurate, and intensive relief, so you can get back to your life quickly and with renewed energy.

See How It Works

0:38

See How It Works

0:38

See How It Works

0:38

OcuTherm® Dry Eye Clinical Study

OcuTherm® Dry Eye Clinical Study

OcuTherm®
Dry Eye Clinical Study

Powerful Symptom Reduction

Results from the 4-week OcuTherm® clinical study are illustrated in the bar graph. All data were published in the journal Investigative Ophthalmology and Visual Science (see Ref. B 1 below).

High rates of user satisfaction, ease of use, sustained heat duration, and use of moisturized heat are the factors most likely to have contributed to the positive outcomes (see Refs. B 2-5 below).

Details and Methods: 30 adult subjects were studied. All had persistent symptoms despite previous dry eye therapy, and were diagnosed with dry eye syndrome related to Meibomian gland dysfunction (MGD) and/or anterior blepharitis. All subjects were provided with OcuTherm kits, and instructed to apply OcuTherm moisturized-heat therapy. Those subjects currently using eye drops and/or oral supplements (e.g., artificial tears, Restasis®, Omega-3 supplements, etc.), were allowed to continue during the study.

Symptoms were evaluated at 0, 2, and 4 weeks using the Ocular Surface Disease Index (OSDI) scale, with the results shown in the bar graph (see Ref. B 6 below). Usage diaries and selected questionnaires were also used.

Powerful Symptom Reduction

Results from the 4-week OcuTherm® clinical study
are shown and discussed below.

Results were published in Investigative Ophthalmology and Visual Science (see ref. B 1 below).

High rates of user satisfaction, ease of use, sustained heat duration, and use of moisturized heat are the factors most likely to have contributed to the positive outcomes (see refs. B 2-5 below).

Details and Methods: 30 adult subjects were studied. All had persistent symptoms despite previous dry eye therapy, and were diagnosed with dry eye syndrome related to Meibomian gland dysfunction (MGD) and/or anterior blepharitis. All subjects were provided with OcuTherm kits, and instructed to apply OcuTherm moisturized-heat therapy. Those subjects currently using eye drops and/or oral supplements (e.g., artificial tears, Restasis®, Omega-3 supplements, etc.), were allowed to continue during the study.

Symptoms were evaluated at 0, 2, and 4 weeks using the Ocular Surface Disease Index (OSDI) scale, with the results shown in the bar graph (see ref. B 6 below). Usage diaries and selected questionnaires were also used.

Powerful Symptom Reduction

Results from the 4-week OcuTherm® clinical study
are shown and discussed below.

Results were published in Investigative Ophthalmology and Visual Science (see ref. B 1 below).

High rates of user satisfaction, ease of use, sustained heat duration, and use of moisturized heat are the factors most likely to have contributed to the positive outcomes (see refs. B 2-5 below).

Details and Methods: 30 adult subjects were studied. All had persistent symptoms despite previous dry eye therapy, and were diagnosed with dry eye syndrome related to Meibomian gland dysfunction (MGD) and/or anterior blepharitis. All subjects were provided with OcuTherm kits, and instructed to apply OcuTherm moisturized-heat therapy. Those subjects currently using eye drops and/or oral supplements (e.g., artificial tears, Restasis®, Omega-3 supplements, etc.), were allowed to continue during the study.

Symptoms were evaluated at 0, 2, and 4 weeks using the Ocular Surface Disease Index (OSDI) scale, with the results shown in the bar graph (see ref. B 6 below). Usage diaries and selected questionnaires were also used.

(A) References

1. Mouraux A, Diukova A, Lee MC, Wise RG, Iannetti GD. NeuroImage 54 (2011) 2237–2249. A multisensory investigation of the functional significance of the pain matrix.

2. Crane AM, Levitt RC, Felix ER, Sarantopoulos KD, McClellan AL, Galor A. Patients with more severe symptoms of neuropathic ocular pain report more frequent and severe chronic overlapping pain conditions and psychiatric disease. Br J Ophthalmol. 2017 Feb;101(2):227-231.

3. Galor A, Levitt RC, Felix ER, Martin ER, Sarantopoulos CD. Neuropathic ocular pain: an important yet under evaluated feature of dry eye. Eye 29:301–312.

4. Schiffman RM, Walt JG, Jacobsen G et al. Utility assessment among patients with dry eye disease. Ophthalmology. 2003 Jul;110(7):1412 9.

5. Galor A, Batawi H, Felix ER, Margolis TP, Sarantopoulos KD, Martin ER, Levitt RC. Incomplete response to artificial tears is associated with features of neuropathic ocular pain. Br J Ophthalmol 2016 100:745–749

6. Ongun N, Ongun GT. Is gabapentin effective in dry eye disease and neuropathic ocular pain? Acta Neurol Belg. 2019 May 27.

7. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011;152(3 Suppl):S2-15.

8. Mendell LM. Constructing and Deconstructing the Gate Theory of Pain. Pain. 2014 February ; 155(2): 210–216.

9. Nolano M, Provitera V, Crisci C, et al. Quantification of myelinated endings and mechanoreceptors in human digital skin. Ann Neurol. 2003 Aug;54(2):197 205.

10. Lauria G, Holland N, Hauer P, et al. Epidermal innervation: changes with aging, topographic location, and in sensory neuropathy. J Neurol Sci. 1999 Apr 1;164(2):172-8.

11. Besné I, Descombes C, Breton L. Effect of Age and Anatomical Site on Density of Sensory Innervation in Human Epidermis. Arch Dermatol. 2002 Nov;138(11):1445-50.

12. Marfurt CF, Cox J, Deek S, Dvorscak L. Anatomy of the human corneal innervation. Exp Eye Res. 2010 Apr;90(4):478 92.

13. Chinwuba I, Tsui E, Mitry M, et al. The OcuTherm System, a Novel At-Home Eyelid Thermal Treatment Device – A 4-Week Clinical Study. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2684.

(B) References

1Chinwuba I, Tsui E, Mitry M, et al. The OcuTherm System, a Novel At-Home Eyelid Thermal Treatment Device – A 4-Week Clinical Study. Presented at the Association of Research in Vision and Ophthalmology (ARVO). Published in: Invest. Ophthalmol. Vis. Sci. 2017;58(8):2684. Click here to view the article.

2Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52:2050–2064.

3 Murakami DK, Blackie CA, Korb DR. All Warm Compresses Are Not Equally Efficacious. Optom Vis Sci. 2015 Sep;92(9):e327-33.

4Blackie CA, Solomon JD, Greiner JV, et al. Inner eyelid surface temperature as a function of warm compress methodology. Optom Vis Sci. 2008 Aug;85(8):675-83.

5Olson MC, Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens. 2003;29:96–99.

6Dougherty BE, Nichols JJ, and Nichols KK. Rasch Analysis of the Ocular Surface Disease Index (OSDI). Invest Ophthalmol Vis Sci. 2011;52:8630–8635.